Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company’s Board of Directors
August 03 2020 - 4:15PM
Royalty Pharma (Nasdaq: RPRX) today announced the appointments of
Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of
Directors, effective immediately. Mr. Fernandez is Chairman and
Chief Executive Officer of MSCI Inc., a leading global provider of
investment decision support tools. Dr. Love is President and Chief
Executive Officer of Global Blood Therapeutics, a biopharmaceutical
company focused on the treatment and care of sickle cell disease.
“Following our successful initial public
offering, we are further strengthening the governance of Royalty
Pharma with the appointments to the Board of Henry Fernandez and
Ted Love," said Pablo Legorreta, Founder and CEO of Royalty Pharma.
“Both are highly entrepreneurial and bring exceptional leadership
qualities achieved over long and successful careers in finance and
the research-based biopharma industry, respectively. Their
experience, knowledge and business acumen will be invaluable to the
company as we continue our journey as the leading funder of
innovation in the biopharma ecosystem," Legorreta added.
In addition to their roles as Board Directors,
Henry Fernandez will join the Audit Committee of the Board and Ted
Love will join the Nominating and Corporate Governance
Committee.
About Henry A. Fernandez
Henry A. Fernandez has served as Director and
Chairman of MSCI Inc. since 2007 and as Chief Executive Officer
since 1998. Before leading MSCI’s transition to becoming a fully
independent, public company in 2007, he was a Managing Director at
Morgan Stanley from 1983 to 1991 and from 1994 to 2007, where he
worked in emerging markets product strategy, equity derivative
sales and trading, mergers and acquisitions, worldwide corporate
finance and mortgage finance for U.S. financial institutions. Mr.
Fernandez serves on the Board of Trustees for Stanford University
as well as Memorial Sloan Kettering Cancer Center. Mr. Fernandez
holds a Bachelor of Arts in economics from Georgetown University,
an M.B.A. from the Stanford University Graduate School of Business
and pursued doctoral studies in economics at Princeton
University.
About Dr. Ted W. Love
Ted W. Love, M.D. joined Global Blood
Therapeutics in 2014 as President and Chief Executive Officer and
also serves on its Board. Previously, he was EVP, Research &
Development and Technical Operations, at Onyx Pharmaceuticals, Inc.
Prior to Onyx, Dr. Love served as President, Chief Executive
Officer and Chairman of Nuvelo, Inc. Among his earlier roles, Dr.
Love served as SVP, Development, at Theravance, Inc. and he held a
number of senior management positions in medical affairs and
product development at Genentech. He holds Board positions at
Amicus Therapeutics, Inc. and the Biotechnology Innovation
Organization, for which he Chairs the Emerging Companies Section.
Dr. Love holds a B.A. in molecular biology from Haverford College
and an M.D. from Yale Medical School. He completed a residency in
internal medicine and a fellowship in cardiology at the
Massachusetts General Hospital.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest
buyer of biopharmaceutical royalties and a leading funder of
innovation across the biopharmaceutical industry, collaborating
with innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four
development-stage product candidates. For more information, visit
www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-2295ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024